

Ad Hoc Announcement pursuant to Sec. 15 WpHG (German Securities Trading Act)

Epigenomics enters strategic license and development agreement with BioChain on novel, blood-based lung cancer test for China

Berlin, Germany, March 30, 2016 - Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) announces that it has entered a strategic license agreement with BioChain on the development and commercialization of a novel, blood-based lung cancer test for China.

BioChain will initiate a clinical trial to validate the lung cancer detection test with the goal to gain market approval by the CFDA. The trial is expected to start in 2016. The product development will be based on Epigenomics' novel panel of blood-based DNA methylation biomarkers that has shown promising results in a clinical validation study.

Under the terms of the agreement, Epigenomics will receive undisclosed upfront, milestone and minimum annual payments as well as mid single-digit royalty on future revenues. Lung cancer diagnosis remains challenging worldwide. In view of the high, rapidly growing prevalence of lung cancer among the Chinese population, the commercialization of a novel, blood-based test represents a major business opportunity for both companies. Epigenomics is entitled to commercialize this product in other markets outside China.

- **End of Ad hoc** -

Contact Epigenomics AG

Peter Vogt, Investor & Public Relations

Epigenomics AG

Geneststraße 5

10829 Berlin

Phone +49 (0) 30 24345 386

ir@epigenomics.com

www.epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.